Suggestions
Dominik Ruettinger
Global Head Research and Early Development Oncology at Bayer Pharmaceuticals
Dominik Ruettinger is a physician-scientist with over 12 years of experience in academia, having worked in both the United States and Germany.1 He currently holds the position of Global Head Research and Early Development Oncology at Bayer Pharmaceuticals.6
Career at Bayer
Ruettinger joined Bayer in December 2022 as the Global Head of Early Clinical Development Oncology.2 His role at Bayer involves overseeing early-stage development in oncology, which he describes as "where innovation begins".2 Since then, he has been promoted to his current position as SVP, Global Head Research and Early Development Oncology.
Focus Areas
Precision Oncology:: Ruettinger is actively involved in Bayer's efforts to advance precision oncology. He has shared updates about Bayer's partnerships and collaborations in this field, including:
- A partnership with Aignostics to develop next-generation precision oncology solutions3
- A strategic collaboration with NextRNA Therapeutics, which Ruettinger expressed excitement about, noting the innovation in this space4
Drug Development:: Ruettinger frequently shares updates on Bayer's progress in drug development, particularly in oncology. For example, he announced when the FDA granted Breakthrough Therapy designation to Bayer's oral, reversible tyrosine kinase inhibitor being developed for non-small cell lung cancer (NSCLC).5
Professional Approach
Ruettinger appears to be passionate about innovation in oncology and precision medicine. He regularly shares updates about Bayer's advancements and collaborations in these areas, demonstrating his engagement with the latest developments in the field. His background as a physician-scientist likely informs his approach to his role at Bayer, combining clinical knowledge with research expertise.
Highlights
It was a true pleasure joining Merel Hennink (Stichting Merels Wereld), Christine Roth and Melinda Crane-Roehrs on stage today at our annual Bayer | Pharmaceuticals Media Day. Merel shared her story of being diagnosed with ROS1 positive lung cancer at the age of 46, approaching her 10-year anniversary of being on treatment very soon. The resilience and insights of young patients like Merel inspired us deeply. Guided by our #precisiondrugdevelopment strategy, we are committed to developing innovative medicines that serve both today’s patients as well as our future patient population, with a focus on improved efficacy AND better tolerability. #teambayer #oncologyinspired
Looking forward to a great prelude to #JPM24 tomorrow with Carolyn M., Sharon Barr and Ajay Nirula at the ongoing Longwood Healthcare Leaders conference in San Francisco. We will be discussing key opportunities and challenges for biopharma R&D in 2024. Speaking of opportunities: I am eagerly anticipating meeting colleagues, learning about cutting edge innovation, and defining new ways to join forces and collaborate creatively in drug discovery and development at this year’s #JPM24 conference!
#longwoodhealthcareleaders, #OncologyInspired, #teambayer
